Steroid sulfatase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 11, 2005, Pages 1541-1553

  Horvath, Amarylla ^a   Billich, Andreas ^a  

^a Novartis Inst for Biomedical Res   (Austria)

Author keywords

Acne; Arylsulfonamide; Cancer; Enzyme; Inhibitor; Oestrogenic activity; Stability; Steroid; Sulfamate; Sulfatase

Indexed keywords

17 DEOXYESTRONE 3 O SULFAMATE; 2 ALKYLCHROMENONE 6 O SULFAMATE; 2 DIFLUOROMETHYLESTRONE; 2 METHOXYESTRADIOL; 3,5 DITRIFLUOROMETHYL DERIVATIVE; ANDROGEN; BENZOTHIOPHENE SULFAMATE; BENZOXAZOLE DERIVATIVE; COUMARIN DERIVATIVE; ESTERASE INHIBITOR; ESTRADIOL SULFAMATE; ESTROGEN; ESTROGEN SULFAMATE; ESTRONE 3 O SULFAMATE; ESTRONE SULFATE; HYDROLASE INHIBITOR; HYDROXYSTEROID; MADURAHYDROXYLACTONE THIOCARBSEMICARBAZONE DERIVATIVE; MICROSOME ENZYME; NORTROPINYL ARYLSULFONYLUREA DERIVATIVE; PIPERAZINE DERIVATIVE; PRASTERONE SULFATE; STERYL SULFATASE; STERYL SULFATASE INHIBITOR; SULFATE; SULFONYLUREA DERIVATIVE; THIOPHOSPHONATE DERIVATIVE; TYRAMINE SULFAMATE DERIVATIVE; TZS 8478; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALOPECIA; ANDROGEN SYNTHESIS; BREAST CANCER; CATALYSIS; CLINICAL TRIAL; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; HIGH THROUGHPUT SCREENING; HIRSUTISM; HUMAN; HYDROLYSIS; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; REVIEW; SKIN DISEASE; STRUCTURE ACTIVITY RELATION;

EID: 27944442875     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.11.1541     Document Type: Review

References (74)

1. PASQUALINI JR, GELLY C, NGUYEN BL, VELLA C: Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. (1989) 34:155-163.
2. REED MJ, PUROHIT A: Sulphatase inhibitors: the rationale for the development of a new endocrine therapy. Rev. Endocr. Relat. Cancer (1993) 45:51-62.
3. REED MJ, PUROHIT A, HOWARTH NM, POTTER BV: Steroid sulphatase inhibitors: a new endocrine therapy. Drugs Fut. (1994) 19:673-680.
4. SUZUKI T, MORIYA T, ISHIDA T, OHUCHI N, SASANO H: Intracrine mechanism of estrogen synthesis in breast cancer. Biomed. Pharmacother. (2003) 57:460-462.
5. NAKATA T, TAKASHIMA S, SHIOTSU Y et al.: Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J. Steroid. Biochem. Mol. Biol. (2003) 86:455-460.
6. SUZUKI T, MIKI Y, NAKATA T et al.: Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J. Steroid Biochem. Mol. Biol. (2003) 86:449-454.
7. PUROHIT A, WOO LWL, CHANDER SK et al.: Steroid sulfatase inhibitors for breast cancer therapy. J. Steroid Biochem. Mol. Biol. (2003) 86:423-432.
8. UTSUMI T, YOSHIMURA N, TAKEUCHI S, MARUTA M, MAEDA K, HARADA N: Elevated steroid sulfatase expression in breast cancers. J. Steroid Biochem. Mol. Biol. (2000) 73:141-145.
9. SUZUKI T, NAKATA T, MIKI Y et al.: Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. (2003) 63:2762-2770.
10. UTSUMI T, YOSHIMURA N, TAKEUCHI S et al.: Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. (1999) 59:377-381.
11. MIYOSHI Y, ANDO A, HASEGAWA S et al.: High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin. Cancer Res. (2003) 9:2288-2293.
12. YOSHIMURA N, HARADA N, BUKHOLM I, KARESEN R, BORRESEN-DALE AL, KRISTENSEN VN: Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Res. (2004) 6:R46-R55.
13. HANKINSON SE, WILLETT WC, MANSON JE et al.: Plasma sex hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. (1998) 90:1292-1299.
14. HOWARTH NM, PUROHIT A, REED MJ, POTTER BV: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. (1994) 37:219-221.
15. ELGER W, SCHWARZ S, HEDDEN A, REDDERSEN G, SCHNEIDER B: Sulfamates of various estrogens - prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. (1995) 55:395-403.
16. PAYNE AH, LAWRENCE CC, FOSTER DL, JAFFE RB: Intranuclear binding of 17β-estradiol and estrone in female ovine pituitaries following incubation with estrone sulfate. J. Biol. Chem. (1973) 248:1598-1602.
17. SAHM UG, WILLIAMS GJ, PUROHIT A et al.: Development of an oral formulation for oestrone 3-O-sulphamate, a potent sulphatase inhibitor. Pharm. Sci. (1996) 2:17-20.
18. ELGER W, BARTH A, HEDDEN A et al.: Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod. Fertil. Dev. (2001) 13:297-305.
19. AHMED S, OWEN CP, JAMES K, PATEL CK: Evidence for the mechanism of the irreversible inhibition of oestrone sulphatase (ES) by aminosulphonate based compounds. J. Steroid Biochem. Mol. Biol. (2002) 80:429-440.
20. CHANDER SK, PUROHIT A, WOO LW, POTTER BY, REED MJ: The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem. Biophys. Res. Commun. (2004) 322:217-222.
21. NUSSBAUMER P, WINISKI AP, BILLICH A: Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2003) 46:5091-5094.
22. IRESON CR, PARISH D, PUROHIT A et al.: Development of a sensitive high-performance liquid chromatography method for the detection of 667COUMATE in vivo. J. Steroid Biochem. Mol. Biol. (2003) 84:337-342.
23. IRESON CR, CHANDER SK, PUROHIT A et al.: Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667COUMATE and its sequestration into red blood cells in rats. Br. J. Cancer (2004) 91:1399-1404.
24. HO YT, PUROHIT A, VICKER N et al.: Inhibition of carbonic anhydrasc II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Commun. (2003) 305:909-914.
25. ABBATE F, WINUM JY, POTTER BV et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:231-234.
26. LLOYD MD, PEDERICK RL, NATESH R et al.: Crystal structure of human carbonic anhydrase II at 1.95 Å resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem J. (2005) 385:715-720.
27. NUSSBAUMER P, BILLICH: Steroid sulfatase inhibitors. Med. Res. Rev. (2004) 24:529-576.
28. REED MJ, PUROHIT A, WOO LW, NEWMAN SP, POTTER BV. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev. (2005) 26:171-202.
29. HANSON SR, BEST MD, WONG C: Enzyme chemistry: sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Ang. Chem. (2004) 43:5736-5763.
30. AHMED, OWEN CP, JAMES K, SAMPSON L, PATEL CK: Review of estrone sulfatase and its inhibitors - an important new target against hormone dependent breast cancer. Curr. Med. Chem. (2002) 9:263-273.
31. PUROHIT A, VERNON KA, WAGENAAR HUMMELINCK AE et al.: The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. (1998) 64:269-275.
32. REED JE, WOO LWL, ROBINSON JJ et al.: 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. (2004) 317:169-175.
33. FISCHER DS, WOO LW, MAHON MF, PUROHIT A, REED MJ, POTTER BV: D-Ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. (2003) 11:1685-1700.
34. FISCHER DS, CHANDER SK, WOO LW et al.: Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J. Steroid Biochem. Mol. Biol. (2003) 84:343-349.
35. WOO LW, PUROHIT A, MALINI B, REED MJ, POTTER BV: Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. (2000) 7:773-791.
36. SHIELDS-BOTELLA J, BONNET P et al: In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J. Steroid Biochem. Mol. Biol. (2003) 84:327-335.
37. PUROHIT A, WOO LW, POTTER BV, REED MJ: In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667COUMATE. Cancer Res. (2000) 60:3394-3396.
38. SCHREINER EP, WOLFF B, WINISKI AP, BILLICH A: 6-[2-(Adamantylidene)-hydroxybenzoxazole]-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:4313-4316.
39. WOO LWL, HOWARTH NM, PUROHIT A, HEJAZ HAM, REED MJ, POTTER BVL: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. (1998) 41:1068-1083.
40. WOO LW, PUROHIT A, REED MJ, POTTER BV: Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J. Med. Chem. (1996) 39:1349-1351.
41. WALTER G, LIEBL R, VON ANGERER E: 2-Phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. (2004) 88:409-420.
42. NUSSBAUMER P, LEHR P, BILLICH A: 2-Substituted 4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J. Med. Chem. (2002) 45:4310-4320.
43. LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of nonsteroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (1996) 59:41-48.
44. SCHREINER EP, BILLICH A: Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:4999-5002.
45. ANDERSON CJ, LUCAS LJ, WIDLANSKI TS: Molecular recognition in biological systems: phosphate esters vs. sulfate esters and the mechanism of action of steroid sulfatases. J. Am. Chem. Soc. (1995) 117:3889-3890.
46. DUNCAN L, PUROHIT A, HOWARTH NM, POTTER BV, REED MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res. (1993) 53:298-303.
47. HOWARTH NM, COOPER G, PUROHIT A, DUNCAN L, REED MJ, POTTER BV: Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone 3-methylthio-phos-phonate, a potent inhibitor of estrone sulfatase. Bioorg. Med. Chem. Lett. (1993) 3:313-318.
48. LI PK, PILLAI R, DIBBELT L: Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids. (1995) 60:299-306.
49. HOWARTH NM, PUROHIT A, REED MJ, POTTER BV: Estrone sulfonates as inhibitors of estrone sulfatase. Steroids (1997) 62:346-350.
50. LI PK, PILLAI R, YOUNG BL, BENDER WH, MARTINO DM, LIN FT: Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids (1993) 58:106-111.
51. DIBBELT L, LI PK, PILLAI R, KNUPPEN R: Inhibition of human placental stearylsulfatase by synthetic analogs of estrone sulfate. J. Steroid. Biochem. Molec. Biol. (1994) 50:261-266.
52. WOO LW, LIGHTOWLER M, PUROHIT A, REED MJ, POTTER BV: Heteroatom-substituted analogues of the active-site directed inhibitor oestra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulfatase by a different mechanism. J. Steroid Biochem. Mol. Biol. (1996) 57:79-88.
53. POIRIER D, BOIVIN RP: 17α-Alkyl- or 17-α-substituted benzyl-17β-estradiols: a new family of estrone sulfatase inhibitors. Bioorg. Med. Chem. Lett. (1998) 9:83-91.
54. BOIVIN RP, LUU-THE V, LACHANCE R, LABRIE F, POIRIER D: Structure-activity relationships of 17α-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem. (2000) 43:4465-4478.
55. CIOBANU LC, BOIVIN RP, LUU-THE V, POIRER D: 3β-Sulfamate derivatives of C19 and C21 steroids bearing a t-butylbenzyl or a benzyl group: synthesis and evaluation as non-estrogenic and non-androgenic steroid sulfatase inhibitors. J. Enzyme Inhib. Med. Chem. (2003) 18:15-26.
56. HORVATH A, NUSSBAUMER P, WOLFF B, BILLICH A: 2-(1-Adamantyl)-4-(thio)chromenone-6-carboxylic acids: potent reversible inhibitors of human steroid sulfarase. J. Med. Chem. (2004) 47:4268-4276.
57. JÜTTEN P, SCHUMANN W, HÄRTL A et al.: A novel type of nonsteroidal estrone sulfatase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1339-1342.
58. LEE W, DeROME M, DeBEAR J et al.: Aryl piperazines: a new class of steroid sulfatase inhibitors for the treatment of hormone-dependent breast cancer. Abstracts of Papers, 226th ACS National Meeting. NY, USA (7-11 September 2003) MEDI-301.
59. NUSSBAUMER P, GEYL D, HORVATH A, LEHR P, WOLFF B, BILLICH A: Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:3673-3677.
60. POIRIER D, CIOBANU LC, MALTAIS R: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (1999) 9:1083-1099.
61. NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (2003) 13:605-625.
62. SMITH HJ, NICHOLLS PJ, SIMONS C, LAIN RL: Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin. Ther. Patents (2001) 11:789-1308.
63. WINUM JY, SCOZZAFAVA A, MONTERO JL, SUPURAN CT: Therapeutic applications of sulfamates. Expert Opin. Ther. Patents (2004) 14:1273-1308.
64. LEESE MP, NEWMAN SP, PUROHIT A, REED MJ, POTTER BV: 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumor agents. Bioorg. Med. Chem. Lett. (2004) 13:3135-3138.
65. HUANG P, FENG L, OLDHAM EA, KEATING MJ, PLUNKETT W: Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 407:390-395.
66. CIOBANU LC, LUU-THE V, MARTEL C, LABRIE F, POIRIER D: Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. (2003) 63:6442-6446.
67. CIOBANU LC, POIRIER D: Solid-phase parallel synthesis of 17α-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker. J. Comb. Chem. (2003) 5:429-440.
68. OKADA M, NAKAGAWA T, IWASHITA S, TAKEGAWA S, FUJII T, KOIZUMI N: Development of novel steroid sulfatase inhibitors I. Synthesis and biological evaluation of biphenyt-4-O-sulfamates. J. Steroid Biochem. Mol. Biol. (2003) 87:141-148.
69. SAITO T, KINOSHITA S, FUJII T et al.: Development of novel steroid sulfatase inhibitors II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. J. Steroid Biochem. Mol. Biol. (2004) 88:167-173.
70. CIOBANU LC, LUU-THE V, POIRER D: Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (2002) 80:339-353.
71. PATEL CK, OWEN CP, AHMED S: The design, synthesis, and in vitro biochemical evaluation of a series of esters of 4-[(aminosulfonyl)oxy]benzoate as novel and highly potent inhibitors of estrone sulfatase. Biochem. Biophys. Res. Commun. (2003) 307:778-781.
72. WOLFF B, BILLICH A, BRUNOWSKY W et al.: Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. Anal. Biochem. (2003) 318:276-284.
73. LEHR P, BILLICH A, WOLFF B, NUSSBAUMER P: N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2005) 15:1235-1238.
74. STANWAY S, PUROHIT A, WOO LW et al.: First phase I trial of a steroid sulfatase inhibitor in breast cancer. J. Clin. Oncol. (2004) 22: (Suppl. 14S) Abstract 64S.